Treating osteoporosis in post-menopausal women: a case approach.
We now have several agents of different classes for treating postmenopausal osteoporosis. In this paper, a case report serves as the focus for a discussion of the risk factors for postmenopausal osteoporosis and of the available therapies.
Keller
Michael I
MI
San Diego Arthritis and Osteoporosis Research, San Diego, CA, USA. Mkellermd@aol.com
D000368:Aged; D019386:Alendronate / Q000627:therapeutic use; D003720:Densitometry; D004164:Diphosphonates / Q000627:therapeutic use*; D012968:Etidronic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008403:Mass Screening; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000175:diagnosis / Q000188:drug therapy*; D020849:Raloxifene Hydrochloride / Q000627:therapeutic use; D000068296:Risedronic Acid; D012307:Risk Factors; D020845:Selective Estrogen Receptor Modulators / Q000627:therapeutic use*; D016896:Treatment Outcome
D004164:Diphosphonates; D020845:Selective Estrogen Receptor Modulators; D020849:Raloxifene Hydrochloride; D000068296:Risedronic Acid; D012968:Etidronic Acid; D019386:Alendronate